COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Since colchicine is known to have anti-inflammatory effects and inflammation is an early
component of acute coronary syndrome (ACS), this study aims to evaluate the acute effects of
low-dose colchicine, in addition to atorvastatin, administered on-admission to statin-naive
patients with non-ST elevation ACS scheduled for early invasive strategy.